Saudi Arabia’s King Abdulaziz Royal Reserve Witnesses Births of Arabian Oryx

The new births of young Arabian Oryx were monitored with satellite-supported tracking devices. SPA
The new births of young Arabian Oryx were monitored with satellite-supported tracking devices. SPA
TT

Saudi Arabia’s King Abdulaziz Royal Reserve Witnesses Births of Arabian Oryx

The new births of young Arabian Oryx were monitored with satellite-supported tracking devices. SPA
The new births of young Arabian Oryx were monitored with satellite-supported tracking devices. SPA

The King Abdulaziz Royal Reserve Development Authority has witnessed the births of the Arabian Oryx. This comes as part of its efforts to enrich biodiversity of the reserve, restore ecological balance and consolidate the concept of environmental sustainability.

The Authority aims to reproduce endangered animals and resettle them in natural reserves, and rehabilitate ecosystems in Saudi Arabia.

This is in line with the comprehensive strategic targets for 2030 for royal reserves, and the outputs of the Saudi Green Initiative (SGI), derived from the Kingdom's Vision 2030.

The new births of young Arabian Oryx, known as "Ghadhid", were monitored with satellite-supported tracking devices.

This confirms the success of the programs for the animals' resettlement in the reserve and their adaptation to their new environment. It leads to the prosperity of vegetation cover, as well as the high environmental awareness among members of local communities.

Saudi Arabia is at the forefront of global centers specialized in the breeding of endangered species and their settlement in their natural habitats in line with international standards.



King Fahd Medical City, Boston Oncology Sign MoU for Localization of Gene and Target Cell Therapy

The MoU was signed by King Fahd Medical City Chief Executive Officer Dr. Fahad AlGhofaili and Boston Oncology Chief Executive Director Dr. Abdullah Bajaaj. SPA
The MoU was signed by King Fahd Medical City Chief Executive Officer Dr. Fahad AlGhofaili and Boston Oncology Chief Executive Director Dr. Abdullah Bajaaj. SPA
TT

King Fahd Medical City, Boston Oncology Sign MoU for Localization of Gene and Target Cell Therapy

The MoU was signed by King Fahd Medical City Chief Executive Officer Dr. Fahad AlGhofaili and Boston Oncology Chief Executive Director Dr. Abdullah Bajaaj. SPA
The MoU was signed by King Fahd Medical City Chief Executive Officer Dr. Fahad AlGhofaili and Boston Oncology Chief Executive Director Dr. Abdullah Bajaaj. SPA

Saudi Arabia’s King Fahd Medical City and Boston Oncology have signed a Memorandum of Understanding (MoU) for a project to localize gene and target cell therapy.

The project will be held at King Fahd Medical City, one of the components of the Riyadh Second Health Cluster, the Saudi Press Agency (SPA) reported Monday.
The MoU was signed by King Fahd Medical City Chief Executive Officer Dr. Fahad AlGhofaili and Boston Oncology Chief Executive Director Dr. Abdullah Bajaaj.

The Saudi Deputy Minister for Planning and Development Eng. Abdulaziz Al-Rumaih attended the signing ceremony at the Saudi Ministry of Health.

AlGhofaili affirmed that the MoU aligns with the Medical City's plans towards the objectives of the Saudi Transformation Program in Healthcare Sector, which contributes to the enhancement of advanced healthcare services provided through the localization of modern techniques in treatment.

"The localization of therapeutic technology in the Kingdom is one of our main goals, which aligns with the Saudi Vision 2030 regarding health transformation programs,” SPA quoted AlGhofaili as saying.

“Therefore, we seek to develop local capabilities in the field of advanced medical treatment and technologies by enhancing cooperation with national and international institutions,” he added.